Rheumatoid arthritis

A Clinician's Pearls and Myths in Rheumatology

Volumn , Issue , 2009, Pages 1-13

  O'Dell, James R ^a   Smolen, Josef S ^b   Aletaha, Daniel ^b   Robinson, Dwight R ^d   St Clair, E William ^c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84889978721     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-84800-934-9_1     Document Type: Chapter

References (82)

1. Aletaha D, Nell VPK, Stamm T, et al Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: Validation of a clinical activity score. Arthritis Res 2005a; 7:R796-R806
2. Aletaha D, Ward MM, Machold KP, et al Remission and active disease in rheumatoid arthritis: Defining criteria for disease activity states. Arthritis Rheum 2005b; 52:2625-2636
3. Aletaha D, Breedveld FC, Smolen JS. The need for new classification criteria for rheumatoid arthritis. Arthritis Rheum 2005c; 52: 3333-3336
4. Aletaha D, Funovits J, Keystone EC, Smolen JS. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 2007; 56(10): 3226-3235
5. Arnett FC, Edworthy SM, Block DA, et al The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-324
6. Avina-Zubieta JA, Choi HK, Sadatsafavi M, et al Risk of cardiovascular mortality in patients with rheumatoid arthritis: A meta-analysis of observational studies. Arthritis Rheum 2008; 59:1690-1697
7. Avnon LS, Abu-Shakra M, Flusser D, et al Pleural effusion associated with RA Rheum International 2007; 27:919-925
8. Axford JS. Rheumatic manifestations of haemochromatosis. Baillieres Clin Rheumatol 1991; 5:351-365
9. Bathon JM, Martin RW, Fleischmann RM, et al A comparison of etanercept and methotrexate in early rheumatoid arthritis. N Engl J Med 2000;343:1586-93
10. Bellhorn LR, Hess EV. Erosive osteoarthritis. Semin Arthritis Rheum 1993; 22:298-306
11. Boers M, Verhoeven AC, Markusse HM, et al Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis: A randomised trial. Lancet 1997; 350:309-318
12. Breedveld F, Agarwal S, Yin M, et al Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol 2007; 47:1119-1128
13. Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006; 65: 983-989
14. Carmichael SJ, Beal J, Day RO, Tett SE. Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate. J Rheumatol 2002; 29: 2031-2033
15. Carter JD, Ladhani A, Ricca LR, et al A safety assessment of tumor necrosis factor antagonists during pregnancy: A review of the Food and Drug Administration database. J Rheumatol 2009; 36:3
16. Chan MT. Owen P. Dunphy J, et al Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC Class II alleles in systemic lupus erythematosus. J Rheumatol 2008; 35 (1):77-83
17. Ching DW, Petrie JP, Klemp P, et al Injection therapy of superficial rheumatoid nodules. Br J Rheumatol 1992; 31:775
18. Choi HK, Hernan MA, Seeger JD, et al Methotrexate and mortality in patients with rheumatoid arthritis: A prospective study. Lancet 2002; 359(9313):1173-1177
19. Cohen SB, Dore RK, Lane NE, et al Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, doubleblind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008; 58(5):1299-1309
20. De Souza AW, Fernendes V, Ferrari AJ. Female gout: Clinical and laboratory features. J Rheumatol 2005; 32:2186-2188
21. Doherty M, Dieppe PA. Crystal deposition disease in the elderly. Clin Rheum Dis 1986; 12:97-116
22. Drossaers-Bakker KW, de Buck M, van Zeben D, et al Long-term course and outcome of functional capacity in rheumatoid arthritis: The effect of disease activity and radiologic damage over time. Arthritis Rheum 1999; 42:1854-1860
23. Fernandez A, Quintana G, Rondon F, et al Lupus arthropathy: A case series of patients with rhupus. Clin Rheumatol 2006; 25:164-167
24. Finckh A, Dehler S, Costenbader KH, et al Cigarette smoking and radiographic progression in rheumatoid arthritis. Ann Rheum Dis 2007; 66:1066-1071
25. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2009 (in press)
26. Genovese MC, Becker JC, Schiff M, et al Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005; 353(11):1114-1123
27. Goekoop-Ruiterman YP, De Vries-Bouwstra JK, Allaart CF, et al Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum 2005; 52: 3381-3390
28. Gomez-Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period. Arthritis Res Ther 2006; 8(1):R29
29. Gonzalez A, Kremers HM, Crowson CS, et al Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis as in non-rheumatoid arthritis patients? Ann Rheum Dis 2006; 67:64-69
30. Grigor C, Capell H, Stirling A, et al Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A singleblind randomised controlled trial. Lancet 2004; 364:263-269
31. Harrison BJ, Symmons DP, Barret EM, Silman AS. The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early infl ammatory polyarthritis. J Rheumatol 1998; 25(2324):2330
32. Hyrich KL, Lunt M, Watson KD, et al Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: Results from a large UK national cohort study. Arthritis Rheum 2007; 56(1):13-20
33. Kalajian A, Callen J. Multicentric reticulohistiocytosis successfully treated with infl iximab: An illustrative case and evaluation of cytokine expression supporting anti-tumor necrosis factor therapy. Arch Dermatol 2008; 144:1360-1366
34. Kirwan JR, The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995; 333: 142-146
35. Klareskog L, Stolt P, Lundberg K, et al A new model for an etiology of rheumatoid arthritis: Smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modifi ed by citrullination. Arthritis Rheum 2006; 54:38-46
36. Kobelt G, Jönsson B. The burden of rheumatoid arthritis and access to treatment: Outcome and cost-utility of treatments. Eur J Health Econ 2008; 8 (Suppl 2):S95-S106
37. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, et al The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000; 43(8):1831-1835
38. Lee H, Irigoyen P, Kern M, et al Interaction between smoking, the shared eiptope, and anti-cyclic citrullinated peptide: A mixed picture in three large North American rheumatoid arthritis cohorts. Arthritis Rheum 2007; 56:1745-1753
39. Li J, Gwilt P. The effect of malignant effusions on methotrexate disposition. Cancer Chemother Pharmacol 2002; 50:373-382
40. Lunardi C, Tinazzi E, Bason C, et al Human parvovirus B19 infection and autoimmunity. Autoimmun Rev 2008; 8:116-120
41. Machold KP, Stamm TA, Nell VP, et al Very recent onset rheumatoid arthritis: Clinical and serological patient characteristics associated with radiographic progression over the fi rst years of disease. Rheumatology (Oxford) 2006 [Epub 2006 Aug 9 ahead of print]
42. Masi, AT. Articular patterns in the early course of rheumatoid arthritis. Am J Med 1983; 75:16
43. Mattey DL, Dawes PT, Clarke S, et al Relationship among the HLADRB1 shared epitope, smoking, and rheumatoid factor production in rheumatoid arthritis. Arthritis Care Res 2002; 47:403-407
44. Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007; 21(5):885-906
45. Mierau M, Schoels M, Gonda G, et al Assessing remission in clinical practice. Rheumatology 2007; 46:975-979 [Epub 2007 Mar 6]
46. Mikuls TR, Huges LB, Westfall AO, et al Cigarette smoking, disease severity, and autoantibody expression in African Americans with recent-onset rheumatoid arthritis. Ann Rheum Dis 2008; 67: 1529-1534
47. Morozzi G, Bellisai F, Fioravanti A, Galeazzi M. Absence of anti-cyclic citrullinated peptide antibodies in erosive osteoarthritis: Further serological evidence of the disease as a subset of osteoarthritis. Ann Rheum Dis 2005; 64:1095-1096
48. Mottonen T, Hannonen P, Leirisalo-Repo M, et al Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. FIN-RACo trial group. Lancet 1999; 353(9164):1568-1573
49. Nell V, Machold KP, Stamm TA, et al Autoantibody profi ling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 2005; 64:1731-1736 [Epub 2005 May 5]
50. Nishimura K, Sugiyama D, Kogata Y, et al Meta-analysis: Diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007; 146:797-808
51. O'Dell J. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334:1287-1291
52. O'Dell R. Is there a role for antibiotics in the treatment of patients with rheumatoid arthritis? Drugs 1999; 57:279-282
53. Ostendorf B, Scherer A, Specker C, et al Jaccoud's arthropathy in systemic lupus erythematosus: Differentiation of deforming and erosive patterns by magnetic resonance imaging. Arthritis Rheum 2003; 48:157-165
54. Padyukov L, Silva C, Stolt P, et al A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum 2004; 50:3085-3092
55. Plant MJ, Jones PW, Saklatvala J, et al Patterns of radiological progression in rheumatoid arthritis: Results of an 8 year prospective study. J Rheumatol 1998; 25:417-426
56. Rantapaa-Dahlqvist S. Diagnostic and prognostic significance of autoantibodies in early rheumatoid arthritis. Scand J Rheumatol 2005;34:83
57. Rau R, Herborn G, Menninger H, Blechschmidt J. Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a doubleblind parallel study of 174 patients. Br J Rheumatol 1997; 36:345-352
58. Rennard SI, Fogarty C, Kelsen S, et al The safety and efficacy of infl iximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175:926-934
59. Saag KG, Cerhan JR, Kolluri S, et al Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis 1997; 56:463-469
60. Schellekens GA, Visser H, de Jong BA, et al The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43:155-163
61. Silman AJ, Newman J, MacGregor AJ. Cigarette smoking increases the risk of rheumatoid arthritis. Arthritis Rheum 1996; 39:732-735
62. Sinclair D, Hull RG. Why do general practitioners request rheumatoid factor? A study of symptoms, requesting patterns and patient outcome. Ann Clin Biochem 2003; 40(Pt 2):131-137
63. Smolen JS, Sokka T, Pincus T, Breedveld FC. A proposed treatment algorithm for rheumatoid arthritis: Aggressive therapy, methotrexate, and quantitative measures. Clin Exp Rheumatol 2003a; 21(5 Suppl 31):S209-S210
64. Smolen JS, Breedveld FC, Schiff MH, et al A simplifi ed disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003b; 42:244-257
65. Smolen JS, Aletaha D, Keystone E. Superior efficacy of combination therapy for rheumatoid arthritis. Fact or Fiction? Arthritis Rheum 2005; 52:2975-2983
66. Smolen JS, Han C, Van der Heijde DM, et al Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infl iximab plus methotrexate: The impacts of remission and TNF blockade. Ann Rheum Dis 2009; (6):823-7
67. Smolen J, Kay J, Doyle MK, et al Golimumab, a new human anti-TNF alpha monoclonal antibody, subcutaneously administered every 4 weeks in patients with active rheumatoid arthritis who were previously treated with anti-TNF-alpha agent(s): Results of the randomized, double-blind, placebo-controlled trial. Ann Rheum Dis 2008b; 67(Suppl II):50
68. Stone JH, Holbrook JT, Marriott MA, et al, for the Wegener's Granulomatosis Etanercept Trial Research Group. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 2006; 54:1608-1618
69. Svensson B, Boonen A, Albertsson K, et al Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two-year randomized trial. Arthritis Rheum 2005; 52:3360-3370
70. Thery C, Lekieffre J, Gosselin B, et al Atrio-ventricular block in rheumatoid polyarthritis. Arch Mal Coeur Vaiss 1974; 67:1181-1191
71. Turesson C, O'Fallon WM, Crowson CS, et al Extra-articular disease manifestation in rheumatoid arthritis: Incidence, trends, and risk factors over 46 years. Ann Rheum Dis 2003; 62:722-727
72. van der Heijde DM, van Riel PL, van Leeuwen MA, et al Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol 1992; 31(8):519-525
73. van der Helm-van Mil AH, le Cessie S, van Dongen H, et al A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: How to guide individual treatment decisions. Arthritis Rheum 2007; 56:433
74. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, Toes RE, Huizinga TW. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: A prospective cohort study. Arthritis Rheum 2004; 50:709-715
75. van Vollenhoven R. Switching between biological agents. Clin Exp Rheumatol 2004; 22(Suppl 5):S115-S121
76. van Vugt RM, Derksen RH, Kater L, Bijlsma JW. Deforming arthropathy or lupus and rhupus hands in systemic lupus erythematosus. Ann Rheum Dis 1998; 57: 540-544
77. Verstappen SM, Jacobs JW, Heurkens AH, et al Intensive treatment with methotrexate in early rheumatoid arthritis: Aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007; 66(11):1443-1449
78. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38(9):1261-1265
79. Wasko MC, Hubert HB, Lingala VB, Elliott JR, Luggen ME, Fries JF, Ward NM. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007; 298:187-193
80. Wassenberg S, Rau R, Steinfeld P, Zeidler H. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: A multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52:3371-3380
81. Yelin E, Trupin L, Wong B, Rush S. The impact of functional status and change in functional status on mortality over 18 years among persons with rheumatoid arthritis. J Rheumatol 2002; 29(9):1851-1857
82. Young NS, Brown KE. Parvovirus B19. N Engl J Med 2004; 350: 586-597